by @dministrator | Jul 3, 2023 | Nevakar Injectables
Nevakar Injectables Announces FDA Approval of Cyclophosphamide RTD Solution Published on: Bridgewater, NJ, July 3, 2023 – Nevakar Injectables Inc. (“Nevakar”), a biopharmaceutical company developing multiple sterile injectable products for use in the critical and...
by @dministrator | May 2, 2022 | Nevakar Injectables
Nevakar Injectables Sells Six Development-Stage, Ready-to-Use Injectable Product Candidates to Endo Ventures Limited Published on: Bridgewater, NJ, May 2, 2022 – Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical...
by @dministrator | Apr 28, 2022 | Nevakar Injectables
Nevakar Injectables Receives U.S. FDA Approval of Ready-to-Use Ephedrine Injection in a Prefilled Syringe Published on: Bridgewater, NJ, USA, April 28, 2022 – Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical...
by @dministrator | Mar 28, 2022 | Nevakar Injectables
Nevakar Injectables Announces the Launch of Ready-to-Use Ephedrine Injection Vials Published on: Bridgewater, NJ, USA, March 28, 2022 – Nevakar Injectables Inc., a biopharmaceutical company developing multiple sterile injectable products for use in the critical and...
by @dministrator | Mar 9, 2022 | Nevakar Injectables
Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance Published on: Bridgewater, NJ, USA, March 9, 2022 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic...
